Return to Clinical Trials Search Results
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Primary Objective:
To determine if SBRT improves overall survival in HCC patients treated with Sorafenib
Secondary Objectives:
To determine the difference in time to progression (TTP) and progression-free survival (PFS) in HCC patients treated with Sorafenib compared to SBRT followed by Sorafenib
To measure differences in toxicity in HCC patients treated with Sorafenib versus SBRT followed by Sorafenib
To measure vascular thrombosis response post Sorafenib versus SBRT followed by Sorafenib
To measure differences in Health Related QOL and quality-adjusted survival in HCC patients treated with Sorafenib compared to SBRT followed by Sorafenib
Collection of biospecimens for future correlative studies to investigate differences in potential biomarkers in patients treated with Sorafenib versus SBRT followed by Sorafenib
Primary Objective:
To determine if SBRT improves overall survival in HCC patients treated with Sorafenib
Secondary Objectives:
To determine the difference in time to progression (TTP) and progression-free survival (PFS) in HCC patients treated with Sorafenib compared to SBRT followed by Sorafenib
To measure differences in toxicity in HCC patients treated with Sorafenib versus SBRT followed by Sorafenib
To measure vascular thrombosis response post Sorafenib versus SBRT followed by Sorafenib
To measure differences in Health Related QOL and quality-adjusted survival in HCC patients treated with Sorafenib compared to SBRT followed by Sorafenib
Collection of biospecimens for future correlative studies to investigate differences in potential biomarkers in patients treated with Sorafenib versus SBRT followed by Sorafenib
Recruitment Status
Past Studies